Helsinn has become one of the world’s leading supportive cancer care companies, with a comprehensive portfolio of oncology products and therapies helping to improve the lives of patients in 90 countries worldwide. We work with a host of longstanding worldwide partners who share our vision and values, with a unique business model combining integrated early- and late-stage licensing programmes to complement our own drug discovery and development.
With over 120 highly skilled R&D personnel, operating within a largely semi-virtual R&D model, we employ an over-proportional number of scientists and physicians compared to other mid-sized European pharmaceutical companies. Thanks to this commitment to R&D, our capabilities are recognized worldwide, from pre-clinical research through all phases of clinical development with proven expertise and focus in cancer care.
The quality of all components, from packaging to APIs, from solvents to excipients, are systematically controlled to meet the most stringent standards in our internal laboratories. We rely on our long-term relationships with trusted suppliers and distributors to deliver consistent quality, while maintaining a sustainable approach.
One of our goals is to build lasting alliances with worldwide partners who share our vision. We are proud to have a very close relationship with all our partners and work together side-by-side to support their activities wherever possible. Among other activities, this includes supporting market access and helping to develop and maintain relationships with key stakeholders.
Helsinn is committed to working with the US cancer-care community, and with this in mind, in 2009 Helsinn Therapeutics was established in New Jersey, USA, through the acquisition of a small biotech company. This important step in the company development has made Helsinn’s first direct presence in the USA territory possible.